Thyroid risk with GLP-1 is a regular concern. Here’s what human versus animal data say. The FDA’s black box warning regarding the risk of C-cell thyroid tumors with GLP-1 agonists has generated understandable concern among patients. This warning is based on animal data. What about… Read more
The risk of pancreatitis with tirzepatide is real but low. Knowing the warning signs is essential for rapid management. Pancreatitis is the most closely monitored potentially serious side effect in patients on GLP-1 agonists. Although the risk is very low (0.1 to 0.2% in clinical trials), acute pancreatitis … Read more
Fatigue with Mounjaro affects approximately 10 to 15% of patients. Discover its causes and how to regain your energy during treatment. Fatigue is an often underestimated side effect of tirzepatide. While rarely mentioned as a reason for discontinuation in clinical studies, it significantly impacts the quality of life of about 10 to 15% … Read more
Nausea is the most common side effect with Mounjaro. Here’s a comprehensive guide to understanding, preventing, and effectively treating it. Between 24% and 33% of patients on tirzepatide experience nausea, primarily at the beginning of treatment and during dose escalations. Although generally transient, this nausea can significantly affect quality of life and lead some patients to discontinue treatment. … Read more
The SUMMIT study demonstrates that tirzepatide significantly improves symptoms and prognosis of heart failure in obese patients. Heart failure with preserved ejection fraction (HFpEF) is one of the most frequent and challenging forms of heart failure to treat, particularly affecting obese patients. The SUMMIT study, published in the New England … Read more
Weight stagnation under Mounjaro is a frequent and predictable phenomenon. Understanding its mechanisms allows it to be overcome. After several months of regular weight loss with tirzepatide, many patients reach a plateau: weight stabilizes despite continued treatment and dietary efforts. This phenomenon, a source of frustration and … Read more
The SURMOUNT-OSA study demonstrates that tirzepatide significantly reduces the severity of obstructive sleep apnea, offering an alternative to mechanical treatments. Obstructive sleep apnea (OSA) affects approximately 30 to 40% of obese individuals. This condition, characterized by repeated interruptions of breathing during sleep, increases cardiovascular risk and significantly deteriorates … Read more
How much weight can one truly lose with Mounjaro? A synthesis of all clinical data available in 2026. The most frequent question from patients considering Mounjaro treatment is simple: how much will I lose? The answer, based on data from 8 major clinical trials involving over 20,000 … Read more
The SURPASS-CVOT study is the largest cardiovascular trial ever conducted with tirzepatide. Its results could transform treatment recommendations. The question of cardiovascular safety for anti-obesity treatments is fundamental. The SURPASS-CVOT (Cardiovascular Outcomes Trial) study was designed to evaluate whether tirzepatide (Mounjaro) reduces the risk of major cardiovascular events in patients … Read more
On GLP-1 treatment (Mounjaro, Ozempic, Wegovy), eating well is essential. Discover menus inspired by French, Spanish, Italian and Brazilian cuisines: high in protein, easy to digest and adapted to every stage of your treatment.
GIP receptors are the key differentiating factor for Mounjaro. Their role in adipose tissue, the brain, and bones explains the superiority of tirzepatide.
Zepbound and Mounjaro contain the same tirzepatide. What are the differences? Indications, reimbursement, availability in France. All you need to know in 2026.